A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass

Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.

Stanford is now accepting new patients for this trial. Please contact David M Axelrod, MD at for more information.

Investigator(s):

Intervention(s):

  • drug : Placebo
  • drug : Aminophylline

Phase: N/A

Eligibility

Ages Eligible For Study:

36 Weeks - 18 Years

Inclusion Criteria

- Less than 18 years old, undergoing cardiac surgery with bypass

External Links

Explore related trials

Contact information

Primary Contact:

David M Axelrod, MD

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: